Summit Therapeutics Inc (SMMT)

Form 8-K - Current report

Form 8-K - Current report

Summit Therapeutics Announces Proposed Public Offering of Common Stock

Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global...

Form 8-K - Current report

Form 8-K - Current report

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to...

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Promising Data Further Support Continued Expansion of Ivonescimab Clinical Development in mCRC Overall Study Population Achieved ORR of 70.8% and...

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic PR Newswire SAN FRANCISCO...

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

Issued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material